Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIRSTANA: Cabazitaxel vs Docetaxel in mCRPC
NCT01308567Phase 3Completed
- Sponsor
- Sanofi
- Start
- May 2011
- Primary completion
- Sep 2015
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 25
01
Overview
A Phase 3 trial of cabazitaxel ginsenoside liposome injection in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Sanofi. Started May 2011; status: completed.
02
Drugs
cabazitaxel ginsenoside liposome injection
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01308567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01308567.